EN 
FR 
GSK licenses Noetik’s OCTO Virtual Cell Foundation Models in $50M Partnership to Advance Cancer R&D
TechBio- Portfolio Company
Jan 8th 2026
Noetik has entered into a five-year licensing agreement with GSK, including $50M in upfront and licensing fees to accelerate cancer drug development.
Noetik is an AI-first TechBio company focused on building generative “world models” from human tissues. Its OCTO-VC foundation models simulate tumor biology to predict patient responses and accelerate drug discovery, positioning Noetik as an innovative AI-biotech partner. “We think that context of the data you’re using to train the models is going to be really impactful”, said Ron Alfa, co-founder and CEO of Noetik.
The company has now secured a $50M USD, five-year licensing deal with the large multinational pharmaceutical company GSK to apply these to non-small cell lung and colorectal cancer research. The agreement reflects a growing shift toward licensing AI-standalone platforms in life sciences and underscores the increasing relevance as viable business partnerships for BioPharma companies.
Press Release- BusinessWire (Jan 8th 2026) “GSK Licenses Noetik’s AI Foundation Models in Anchor Partnership to Transform Cancer Therapeutic Research and Development”
Manon Boisclair MS, MBA, ICD.D
Linearis Ventures- General Partner